CSIMarket


Urogen Pharma Ltd   (URGN)
Other Ticker:  
 


 

Urogen Pharma Ltd

URGN's Financial Statements and Analysis



Urogen Pharma Ltd increased first quarter of 2023 net loss per share of $-1.30 compare to net loss per share of $-1.25 recorded in the same quarter a year ago a decrease compare to $-1.23 realized in previous quarter.


first quarter of 2023
Earnings Per Share Revenues
$ -1.3 $  17 Mill
$-0.05     $+4M     +26.75 %



Urogen Pharma Ltd 's Revenue rose by 26.75 % in first quarter of 2023 (Mar 31 2023) year on year, to $17 million and declined by -4.97 % sequentially.


Urogen Pharma Ltd is Expected to report next financial results on August 10, 2023.

More on URGN's Income Statement



Urogen Pharma Ltd 's in thefirst quarter of 2023 recorded net loss of $-30.213 million, an increase from net loss of $-28.392 million in I. Quarter a year ago.

Sequentially net loss advanced

More on URGN's Growth

Urogen Pharma Ltd Inventories
Inventories grew by 14.93 % to $5 million from I. Quarter a year ago, sequentially inventories rose by 26.38 %. In Mar 31 2023 company's net cash and cash equivalents decreased by $-19 million, capital expenditures grew by -8.00%, to $0 millions compare to same quarter a year ago and fell by 76.92% from IV. Quarter (Dec 31 2022).

More on URGN's Cash flow Statement


Urogen Pharma Ltd does not pay out common stock dividend.

In trailing twelve-month period Urogen Pharma Ltd payed $ -3.84 cash per share, on a free-cash flow basis .


Tangible Book value fell to $ -5.01 per share from $ -3.80.

Company repurchased 0.23 million shares or 0.99 % in Mar 31 2023.


More on URGN's Dividends

 Market Capitalization (Millions) 271
 Shares Outstanding (Millions) 23
 Total Debt (Millions $) 98
 Revenue (TTM) (Millions $) 68
 Net Income (TTM) (Millions $) -112
 Cash Flow (TTM) (Millions $) -69
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Urogen Pharma Ltd does not pay out common stock dividend.

In trailing twelve-month period Urogen Pharma Ltd had negative $ -3.84 cash flow per share, on a free-cash flow basis .


Tangible Book value fell to $ -5.01 per share from $ -3.80.

Company repurchased 0.23 million shares or 0.99 % in Mar 31 2023.


More on URGN's Balance Sheets

 Market Capitalization (Millions) 271
 Shares Outstanding (Millions) 23
 Total Debt (Millions $) 98
 Revenue (TTM) (Millions $) 68
 Net Income (TTM) (Millions $) -112
 Cash Flow (TTM) (Millions $) -69
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


Date modified: 2023-05-14T06:11:15+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071